{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:24:24Z","timestamp":1767705864301},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[1986,9,1]],"date-time":"1986-09-01T00:00:00Z","timestamp":525916800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother. Pharmacol."],"published-print":{"date-parts":[[1986,9]]},"DOI":"10.1007\/bf00253061","type":"journal-article","created":{"date-parts":[[2004,10,3]],"date-time":"2004-10-03T13:37:35Z","timestamp":1096810655000},"page":"39-43","source":"Crossref","is-referenced-by-count":25,"title":["Pharmacokinetic and endocrinological parameters of a slow-release depot preparation of the GnRH analogue ICI 118630 (Zoladex) compared with a subcutaneous bolus and continuous subcutaneous infusion of the same drug in patients with prostatic cancer"],"prefix":"10.1007","volume":"18","author":[{"given":"Timothy J.","family":"Perren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard N.","family":"Clayton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Blackledge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynne C.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Holder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. S.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David G.","family":"Arkell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Cottam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Farrar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clive H.","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0140-6736(83)90387-2","volume":"2","author":"SR Ahmed","year":"1983","unstructured":"Ahmed SR, Brooman PJC, Shalet SM, Howell A, Blacklock NJ (1983) Treatment of advanced prostatic cancer with LHRH analogue ICI 118630: clinical response and hormonal mechanism. Lancet 2: 415?418","journal-title":"Lancet"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1136\/bmj.286.6378.1607","volume":"286","author":"JM Allen","year":"1983","unstructured":"Allen JM, O'Shea JP, Mashiter K, Wiliams G, Bloom SR (1983) Advanced carcinoma of the prostate: treatment with a gonadotrophin-releasing hormone agonist. Br Med J 286: 1607?1609","journal-title":"Br Med J"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0140-6736(82)92279-6","volume":"1","author":"V Borgmann","year":"1982","unstructured":"Borgmann V, Hart W, Schmidt-Gollwitzer M, Adenauer H, Nagel R (1982) Sustained suppression of testosterone production by the lutenising-hormone releasing hormone agonist Buserelin in patients with advanced prostate carcinoma. Lancet 1: 1097?1099","journal-title":"Lancet"},{"key":"CR4","first-page":"17","volume":"209","author":"RN Clayton","year":"1984","unstructured":"Clayton RN (1984) Hypothalmic releasing hormones: therapeutic potential of gonadotrophin releasing hormone: a review. Q J Med 209: 17?27","journal-title":"Q J Med"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1365-2265.1985.tb00144.x","volume":"22","author":"RN Clayton","year":"1985","unstructured":"Clayton RN, Bailey LC, Cottam J, Arkell D, Perren TJ, Blackledge GRP (1985) A radioimmunoassay for a GnRH agonist analogue in serum of patients with prostate cancer treated with D-Ser (tBu) 6 AZA Gly 10 GnRH. Clin Endocrinol 22: 453?462","journal-title":"Clin Endocrinol"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(84)92435-8","volume":"1","author":"A Kahan","year":"1984","unstructured":"Kahan A, Delrieu F, Amor B, Chiche R, Stey A (1984) Disease flare induced by D-Trp6-LHRH analogue in patients with prostatic cancer. Lancet 1: 971?972","journal-title":"Lancet"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1136\/bmj.289.6443.468","volume":"289","author":"D Kerle","year":"1984","unstructured":"Kerle D, Williams G, Ware H, Bloom SR (1984) Failure of long term lutenising hormone releasing hormone treatment for prostatic cancer to suppress serum lutenising hormone and testosterone. Br Med J 289: 468?469","journal-title":"Br Med J"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1073\/pnas.81.12.3861","volume":"81","author":"F Labrie","year":"1984","unstructured":"Labrie F, Dupont A, Belanger A, Emond J, Monfette G (1984) Simultaneous administration of pure antiandrogens, a combination necessary for the use of lutenizing hormone releasing hormone agonists in the treatment of prostate cancer. Proc Natl Acad Sci USA 81: 3861?3863","journal-title":"Proc Natl Acad Sci USA"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1056\/NEJM198411153112004","volume":"311","author":"Leuprolide Study Group","year":"1984","unstructured":"Leuprolide Study Group (1984) Leuprolide versus diethylstilboestrol for metastatic prostate cancer. N Engl J Med 311: 1281?1286","journal-title":"N Engl J Med"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1210\/jcem-58-2-397","volume":"58","author":"RJ Santen","year":"1984","unstructured":"Santen RJ, Demers LM, Max DT, Smith J, Stein BS, Glode LM (1984) Long-term effects of administration of a gonadotrophin-releasing hormone superagonist analog in men with prostatic carcinoma. J Clin Endocrinol Metab 58: 397?400","journal-title":"J Clin Endocrinol Metab"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0140-6736(83)90386-0","volume":"2","author":"KJ Walker","year":"1983","unstructured":"Walker KJ, Nicholson RI, Turkes AO, Turkes A, Griffiths K (1983) Therapeutic potential of the LHRH agonist, ICI 118630 in the treatment of advanced prostatic carcinoma. Lancet 2: 413?415","journal-title":"Lancet"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1677\/joe.0.103R001","volume":"103","author":"KJ Walker","year":"1984","unstructured":"Walker KJ, Turkes AO, Turkes A, Zwink R, Beacock C, Buck AC, Peeling WB, Griffiths K (1984) Treatment of patients with advanced cancer of the prostate using a slow release (depot) formulation of the LHRH agonist ICI 118630 (Zoladex). J Endocrinol 103: R1-R4","journal-title":"J Endocrinol"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1136\/bmj.286.6374.1309","volume":"286","author":"JH Waxman","year":"1983","unstructured":"Waxman JH, Wass JAH, Hendry WF, Besser GM, Malpas JS, Oliver RTD (1983) Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer. Br Med J 286: 1309?1312","journal-title":"Br Med J"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1136\/bmj.291.6506.1387","volume":"291","author":"J Waxman","year":"1985","unstructured":"Waxman J, Man A, Hendry WF, Whitfield HN, Besser GM, Tipstaff RC, Paris AMI, Oliver RTD (1985) Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer. Br Med J 291: 1387?1388","journal-title":"Br Med J"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0022-5347(17)50832-0","volume":"131","author":"H Winfield","year":"1984","unstructured":"Winfield H, Trachtenberg J (1984) A comparison of a powerful lutenising hormone analogue agonist and oestrogen in the treatment of advanced prostatic cancer. J Urol 131: 1107?1109","journal-title":"J Urol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00253061.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00253061\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00253061","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T11:56:37Z","timestamp":1554292597000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00253061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1986,9]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1986,9]]}},"alternative-id":["BF00253061"],"URL":"https:\/\/doi.org\/10.1007\/bf00253061","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[1986,9]]}}}